MARKETS
S&P 5007,619.4+1.31%
NASDAQ 10028,374.3+2.28%
DOW 3052,486.5+0.49%
NIKKEI 22560,819.4-0.70%
DAX26,662.8+1.20%
FTSE 10010,835.5+0.78%
Equities

Ligand’s 51% Royalty Gain Extends Beyond the XOMA Deal

Ligand’s existing royalties grew 25% as XOMA added revenue, while acquisition costs and investment marks helped push reported earnings into a loss.

Derek Fontaine 3 min read
technology, exams, group, biology, medical, laboratory, science, pathologist, laboratory, laboratory, laboratory, laboratory,

Ligand Pharmaceuticals reported third-quarter royalty revenue of $70.3 million, up 51%, as acquired XOMA assets and growth in existing products supported a higher adjusted earnings outlook.

Ligand Pharmaceuticals (LGND) raised its full-year adjusted earnings outlook after royalty revenue climbed 51% to $70.3 million in the third quarter, with growth extending beyond its acquisition of XOMA.

Existing royalty assets generated $58.1 million, up 25% from a year earlier. XOMA’s acquired assets contributed $12.3 million during roughly 11 weeks following the July 14 closing. That distinction matters: the acquisition expanded Ligand’s revenue base, but the existing portfolio also delivered substantial growth.

Management now expects 2026 adjusted diluted earnings of $9.50 to $9.75 per share, compared with its previous range of $9.00 to $9.50. Total revenue guidance remained at $270 million to $310 million, according to the company’s earnings call transcript carried by Motley Fool.

Filspari leads growth, with an estimate still to settle

Filspari became Ligand’s largest royalty asset, generating an estimated $16.8 million for the quarter, up 85% from a year earlier. Management identified its launch in focal segmental glomerulosclerosis, or FSGS, as a primary growth driver following approval in April.

That estimate carries an important qualification. Ligand based it on analyst sales forecasts because partner Travere had not yet reported quarterly sales or supplied a royalty amount. Travere was scheduled to report November 2, and any difference from Ligand’s estimate would be adjusted in the fourth quarter.

Ligand based it on analyst sales forecasts because partner Travere had not yet reported quarterly sales or supplied a royalty amount.

Kyprolis contributed $10.5 million in royalties, while Ojemda and Ohtuvayre each contributed $7 million. XOMA brought Ligand the commercial assets Vabysmo, Ojemda and Miplyffa, as well as more than 100 pipeline programs, broadening both current income sources and potential future royalties.

The acquisition also changed the accounting mix. Ligand’s financial royalty asset balance rose to approximately $800 million from $200 million in the previous quarter. Income recognized on those assets depends on forecasts of royalty cash flows over their lives rather than solely on partner sales in an individual quarter. Quarterly recognized income therefore should not be read as a direct measure of underlying drug-sales growth.

Higher adjusted outlook contrasts with a reported loss

Adjusted diluted earnings fell to $2.67 per share from $3.09 a year earlier. The comparison included $24.5 million of one-time Zelsuvmi out-license income in the prior-year quarter.

The same item affected revenue comparisons. Total core revenue fell 9% to $78.7 million, but grew 26% when that prior-year income was excluded.

Under generally accepted accounting principles, Ligand recorded a $28.5 million net loss, or $1.43 per share. General and administrative expenses reached $72.6 million, including $35 million of one-time XOMA transaction and integration costs. Nonoperating expense totaled $28.3 million, primarily reflecting noncash changes in the market value of equity investments.

Those charges help explain why rising royalties and a higher adjusted earnings forecast coincided with a reported loss. They also make integration spending and investment valuations important alongside product-level royalty performance.

Capital gives Ligand room for more deals

Ligand ended the quarter with approximately $450 million in cash, cash equivalents and short-term investments. Including equity holdings and its credit facility, management put deployable capital at approximately $750 million after issuing $700 million of zero-coupon convertible notes and paying cash for XOMA.

The $730 million XOMA acquisition was Ligand’s largest transaction. The company also completed an AvenCell CAR-T platform financing and acquired a commercial royalty interest in Ryjunea, a pediatric myopia treatment.

Ligand now has more than 200 commercial, clinical and preclinical royalty assets. Management anticipates up to seven pivotal trial readouts through 2027, five originating from XOMA. The acquisition’s longer-term contribution will therefore depend not only on its commercial royalties, but also on whether those inherited development programs succeed.

Key facts

  • Third-quarter royalties: $70.3 million, up 51% year over year
  • Legacy portfolio growth: Royalties rose 25% to $58.1 million
  • 2026 adjusted EPS guidance: $9.50–$9.75 per share
  • Deployable capital: Approximately $750 million, including equity holdings and a credit facility

Sources

Photo: fernandozhiminaicela · Pixabay Content License — source

Filed under Equities

More on Equities

See all →